Melfalan Tillomed Pharma

Melphalan, the active ingredient in Melfalan Tillomed Pharma, is an alkylating agent (nitrogen mustard) presented as an injectable solution for intraarterial and intravenous use. It is employed in the treatment of certain hematologic and solid tumours, including multiple myeloma, ovarian cancer and malignant melanoma. GNH USA supplies Melfalan Tillomed Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melfalan Tillomed Pharma is an alkylating chemotherapy agent used in specific cancer pathways. - Multiple myeloma: helps achieve disease control and prolong survival in eligible patients. - Ovarian cancer: used as part of combination regimens to reduce tumour burden. - Malignant melanoma: employed in selected cases to induce tumour regression.

Melfalan Tillomed Pharma may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: reduced white blood cells, red cells, and platelets leading to infection risk and anemia. - Fatigue: persistent tiredness affecting daily activities. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Secondary malignancies: potential development of new cancers after prolonged exposure. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: rare lung inflammation or fibrosis. - Renal impairment: possible decline in kidney function with high cumulative doses.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for complications. - Baseline blood counts: assess hematologic status prior to each cycle. - Renal function: check serum creatinine and adjust dosing if needed. - Hepatic function: monitor liver enzymes for potential toxicity. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss contraception. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan may interact with other agents, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: risk of infection due to immunosuppression. - High‑dose radiation: increased tissue toxicity when combined.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may increase melphalan plasma levels. - Nephrotoxic drugs (e.g., cisplatin): monitor renal function closely. - CYP450 inducers or inhibitors: may affect drug metabolism, requiring dose adjustments.